Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerati...
BioCardia, Inc., headquartered in San Carlos, C...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-stage biotechnology company focused ...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-s...
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, d...
Rigel Pharmaceuticals, Inc. is a biotechnology ...
We have specialized in dermatology, as your skin's health is our concern. We aim t...
We have specialized in dermatology, as your ski...
Ocugen is a clinical stage biopharmaceutical company focused on discovering, devel...
Ocugen is a clinical stage biopharmaceutical co...
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...
IMV Inc. is a clinical stage biopharmaceutical ...
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies t...
At Aethlon Medical, we are a leading developer ...
Join the National Investor Network and get the latest information with your interests in mind.